Serina Therapeutics Inc.
SER
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.93M
Close$
$0.28
84.3% downside
Current Fair Value
84.3% downsideOvervalued by 84.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.93 Million |
|---|---|
| Enterprise Value | $-4,433,667.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 1.15 |
| Outstanding Shares | 12,047,000 |
Return
| Return on Equity | -122.29% |
|---|---|
| Return on Assets | -78.97% |
| Return on Invested Capital | -91.09% |
Valuation & Multiples
| P/E Ratio | -1.04 |
|---|---|
| PEG | -2.36 |
| Price to Sales | - |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | -34.11 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 19, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.45%▲ 10.30% |
|---|---|
| Total Invested | $2.86M▲ 247.60% |
| Investors Holding | 25▲ 3.00% |
ESG Score
No data
About Serina Therapeutics Inc.
12 employees
CEO: Michael West agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic cand...